Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20593116 | 0.98 | CYP19A1 (0.53) | CYP19A1TBXAS1LOXL2MAPTKDM4E | |
| SCHEMBL6223283 | 0.86 | LOXL2 (0.71) | LOXL2MAPTKDM4EFERMT2LMNA | |
| Trifluoroacetic Acid SCHEMBL20562445 | 0.85 | CYP19A1 (0.43) | CYP19A1TBXAS1LOXL2KDM4ELMNA | |
| Hydrochloric Acid SCHEMBL20592932 | 0.85 | LOXL2 (0.69) | LOXL2MAPTKDM4EFERMT2LMNA | |
| SCHEMBL31038391 | 0.84 | LOXL2 (0.74) | CYP19A1TBXAS1LOXL2MAPTKDM4E | |
| SCHEMBL3288710 | 0.84 | LOXL2 (0.74) | CYP19A1TBXAS1LOXL2MAPTKDM4E | |
| SCHEMBL6114797 | 0.81 | CYP19A1 (0.54) | CYP19A1TBXAS1LOXL2MAPTKDM4E | |
| SCHEMBL5500729 | 0.81 | CYP19A1 (0.54) | CYP19A1TBXAS1LOXL2MAPTKDM4E | |
| SCHEMBL6970292 | 0.81 | CYP19A1 (0.54) | CYP19A1TBXAS1LOXL2MAPTKDM4E | |
| SCHEMBL5537149 | 0.81 | CYP19A1 (0.54) | CYP19A1TBXAS1LOXL2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1451009-A | Glucocortiocoid-selective antinflammatory agents | ABBOTT LAB (US) | 2003-10-22 | — | — | CN | claimed |
| CN-1119348-C | glucocorticoid derivatives, compositions and uses thereof | ABBOTT INC (US) | 2003-08-27 | — | — | CN | claimed |
| EP-1299392-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | Abbott Laboratories (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2002002565-A2 | GLUCOCORTIOCOID-SELECTIVE ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 2002-01-10 | — | — | WO | claimed |
| CN-1296486-A | Glucocorticoid-selective anti-inflammatory agents | ABBOTT LAB (US) | 2001-05-23 | — | — | CN | claimed |
| EP-2772480-B2 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2020-12-09 | — | — | EP | disclosed |
| EP-2772480-B1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-7629358-B2 | Compounds useful for the treatment of diseases | PFIZER INC (US) | 2009-12-08 | — | — | US | disclosed |
| WO-2007005887-A2 | ANDROGEN RECEPTOR MODULATOR COMPOUNDS, COMPOSITIONS AND USES THEREOF | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1727789-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | Pfizer Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| US-20050234097-A1 | Compounds useful for the treatment of diseases | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| CN-1451009-A | Glucocortiocoid-selective antinflammatory agents | ABBOTT LAB (US) | 2003-10-22 | — | — | CN | disclosed |
| CN-1119348-C | glucocorticoid derivatives, compositions and uses thereof | ABBOTT INC (US) | 2003-08-27 | — | — | CN | disclosed |
| CN-1422953-A | Gene sequence of Japanese shistosome China mainland strain gynecophoric canal protein | SHANGHAI DOMESTIC ANIMAL PARAS (CN) | 2003-06-11 | — | — | CN | disclosed |
| CN-1296486-A | Glucocorticoid-selective anti-inflammatory agents | ABBOTT LAB (US) | 2001-05-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234097-A1 | Compounds useful for the treatment of diseases | LTC4S, CYP11B2, CYP11B1 | CYP19A1 80/4885TBXAS1 221/4885LOXL2 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.